Double-Duty diet drug? new pill aims to supercharge weight loss
NCT ID NCT07220629
Summary
This study is testing if a new oral drug called NT-0796 can help people with obesity lose more weight when added to the injectable medication semaglutide (like Wegovy/Ozempic). About 80 participants will take either NT-0796 or a placebo pill twice daily for 6 months, while everyone also receives semaglutide and follows a reduced-calorie diet with increased exercise. The main goals are to see if the combination is safe and if it leads to greater weight loss compared to semaglutide alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigative Site
Mesa, Arizona, 85225, United States
-
Investigative Site
Cooper City, Florida, 33024, United States
-
Investigative Site
Hialeah, Florida, 33016, United States
-
Investigative Site
Jacksonville, Florida, 32216, United States
-
Investigative Site
Miami, Florida, 33147, United States
-
Investigative Site
Marrero, Louisiana, 70006, United States
-
Investigative Site
Columbus, Ohio, 43213, United States
-
Investigative Site
Seabrook, Texas, 77586, United States
-
Investigative Site
Salt Lake City, Utah, 84124, United States
-
Investigative Site
Manassas, Virginia, 20110, United States
Conditions
Explore the condition pages connected to this study.